Cargando…
Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits
Acromegaly is a rare disease characterized by excessive growth hormone secretion, usually from a pituitary tumor. Treatment options include surgery, medical therapy, and in some cases, radiation therapy. Current medical therapy consists of treatment with somatostatin analog medications or a growth h...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269320/ https://www.ncbi.nlm.nih.gov/pubmed/22298946 http://dx.doi.org/10.2147/PPA.S20783 |
_version_ | 1782222457658146816 |
---|---|
author | Carmichael, John D |
author_facet | Carmichael, John D |
author_sort | Carmichael, John D |
collection | PubMed |
description | Acromegaly is a rare disease characterized by excessive growth hormone secretion, usually from a pituitary tumor. Treatment options include surgery, medical therapy, and in some cases, radiation therapy. Current medical therapy consists of treatment with somatostatin analog medications or a growth hormone receptor antagonist. There are two somatostatin analogs currently in use, octreotide and lanreotide. Both are supplied in long-acting formulations and are of comparable biochemical efficacy. Lanreotide is supplied in a prefilled syringe and is injected into deep subcutaneous tissue. Studies have been conducted to assess the efficacy of self- or partner administration, and have demonstrated that injection of lanreotide can be accomplished reliably and safely outside a physician’s office. For patients who have achieved biochemical control with lanreotide, the FDA has recently approved an extended dosing interval. Selected patients may be able to receive the medication less frequently with injections of 120 mg administered every 6 or 8 weeks. This review focuses on the use of lanreotide in the treatment of acromegaly, the safety and efficacy of the drug, and the benefits afforded to patients because of unique aspects of the delivery of lanreotide. |
format | Online Article Text |
id | pubmed-3269320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-32693202012-02-01 Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits Carmichael, John D Patient Prefer Adherence Review Acromegaly is a rare disease characterized by excessive growth hormone secretion, usually from a pituitary tumor. Treatment options include surgery, medical therapy, and in some cases, radiation therapy. Current medical therapy consists of treatment with somatostatin analog medications or a growth hormone receptor antagonist. There are two somatostatin analogs currently in use, octreotide and lanreotide. Both are supplied in long-acting formulations and are of comparable biochemical efficacy. Lanreotide is supplied in a prefilled syringe and is injected into deep subcutaneous tissue. Studies have been conducted to assess the efficacy of self- or partner administration, and have demonstrated that injection of lanreotide can be accomplished reliably and safely outside a physician’s office. For patients who have achieved biochemical control with lanreotide, the FDA has recently approved an extended dosing interval. Selected patients may be able to receive the medication less frequently with injections of 120 mg administered every 6 or 8 weeks. This review focuses on the use of lanreotide in the treatment of acromegaly, the safety and efficacy of the drug, and the benefits afforded to patients because of unique aspects of the delivery of lanreotide. Dove Medical Press 2012-01-18 /pmc/articles/PMC3269320/ /pubmed/22298946 http://dx.doi.org/10.2147/PPA.S20783 Text en © 2012 Carmichael, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Carmichael, John D Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits |
title | Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits |
title_full | Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits |
title_fullStr | Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits |
title_full_unstemmed | Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits |
title_short | Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits |
title_sort | lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269320/ https://www.ncbi.nlm.nih.gov/pubmed/22298946 http://dx.doi.org/10.2147/PPA.S20783 |
work_keys_str_mv | AT carmichaeljohnd lanreotidedepotdeepsubcutaneousinjectionanewmethodofdeliveryanditsassociatedbenefits |